Precision Lung Cancer Logo

Day Two: Tuesday October 30, 2018

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Biomarkers & Companion Diagnostics

8:30

Biomarkers in cancer immunotherapy: challenges and opportunities


Enrique Zudaire

Associate Scientific Director


Janssen

9:00


Speaker TBA

Novartis

9:30

ctDNA applications in EGFR mutant Lung Cancer

 

Juliann Chmielecki

Associate Director, Translational Science

 

AstraZeneca

10:00

Engineered T-cell Therapy for Treatment of NSCLC

 

Steven Piccoli

Head, Clinical Biomarkers, Experimental Medicines

 

Glaxo Smith Kline

10:30


Speaker TBA

Novel Diagnostic Approach

MORNING REFRESHMENTS & SPEED NETWORKING

11:00

11:30

The use of neoantigens for treatmernt and tracking of cancer patients

 

John Castle

Head of Translational Medicine and Bioinformatics

 

Agenus

12:00

Title TBA

Dr. Sean Downing
Director of Customer Engagement

Ultivue

LUNCH & NETWORKING

12:10

PANEL DISCUSSION

1:00

Novel Approaches

1:30

Discovering New Cancer Therapeutics by Targeting Stress Response and the NADome

 

Heike Keilhack

Vice President, Translational Sciences

 

Ribon Therapeutics

2:00

Precision targeted therapy with BLU-667for RET driven cancers

 

Erica Evans

Senior Director, Biology


Blueprint Medicines

AFTERNOON REFRESHMENTS & NETWORKING

2:30

3:00

CNS Metastases:  Challenges and novel approaches in dealing with this major driver of morbidity and mortality in lung cancer patients

 

Jeffrey Bacha

Co-Founder

DelMar Pharmaceuticals

3:30

Developing new therapies through partnerships: A case study with BOS172738, a selective RET inhibitor in Phase I for RET positive NSCLC

 

Keith Wilcoxen

Vice President, Diligence and Non-clinical Development

 

Boston Pharmaceuticals

 

4:00

Design and Synthesis of Novel Tubulysin Payloads and Site Specific Antibody Drug Conjugates Overcoming In-Vivo Acetate Liability.

 

Carolyn Leverett

Principal Scientist

 

Pfizer

 

4:30

Therapeutic Antibodies to novel embryonic targets in lung cancer

 

William Mike Schopperle

CEO and Founder

CureMeta

 

SUMMARY & CLOSE OF CONFERENCE

5:00

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF